484 related articles for article (PubMed ID: 15788493)
1. Safety in numbers--monitoring risk in approved drugs.
Okie S
N Engl J Med; 2005 Mar; 352(12):1173-6. PubMed ID: 15788493
[No Abstract] [Full Text] [Related]
2. FDA attempting to overcome major roadblocks in monitoring drug safety.
Zielinski SL
J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
[No Abstract] [Full Text] [Related]
3. Opening Pandora's pillbox: using modern information tools to improve drug safety.
Gottlieb S
Health Aff (Millwood); 2005; 24(4):938-48. PubMed ID: 16012136
[TBL] [Abstract][Full Text] [Related]
4. Importance and challenges of studying marketed drugs: what is a phase IV study? Common clinical research designs, registries, and self-reporting systems.
Glasser SP; Salas M; Delzell E
J Clin Pharmacol; 2007 Sep; 47(9):1074-86. PubMed ID: 17766697
[TBL] [Abstract][Full Text] [Related]
5. The US Food and Drug Administration's Sentinel Initiative: expanding the horizons of medical product safety.
Robb MA; Racoosin JA; Sherman RE; Gross TP; Ball R; Reichman ME; Midthun K; Woodcock J
Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():9-11. PubMed ID: 22262587
[No Abstract] [Full Text] [Related]
6. MedWatch. On lookout for medical product problems.
Ropp KL
FDA Consum; 1993 Nov; 27(9):14-7. PubMed ID: 10130376
[No Abstract] [Full Text] [Related]
7. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
Wysowski DK; Swartz L
Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
[TBL] [Abstract][Full Text] [Related]
8. Strategy for surveillance of adverse drug events.
Bright RA
Food Drug Law J; 2007; 62(3):605-16. PubMed ID: 17915403
[No Abstract] [Full Text] [Related]
9. Drug safety. Gaps in the safety net.
Couzin J
Science; 2005 Jan; 307(5707):196-8. PubMed ID: 15653480
[No Abstract] [Full Text] [Related]
10. Canadian and US drug approval times and safety considerations.
Rawson NS; Kaitin KI
Ann Pharmacother; 2003 Oct; 37(10):1403-8. PubMed ID: 14519031
[TBL] [Abstract][Full Text] [Related]
11. Prescription for trouble: common drugs, hidden dangers. Tens of people are at risk.
Consum Rep; 2006 Jan; 71(1):34-9. PubMed ID: 16491527
[No Abstract] [Full Text] [Related]
12. Toward improved adverse event/suspected adverse drug reaction reporting.
Gross R; Strom BL
Pharmacoepidemiol Drug Saf; 2003 Mar; 12(2):89-91. PubMed ID: 12642971
[No Abstract] [Full Text] [Related]
13. Regulatory considerations for determining postmarketing study commitments.
Meyer RJ
Clin Pharmacol Ther; 2007 Aug; 82(2):228-30. PubMed ID: 17538552
[TBL] [Abstract][Full Text] [Related]
14. The impact of FDA reform.
Trunzo J
Med Device Technol; 2003 Apr; 14(3):36-7. PubMed ID: 12789699
[TBL] [Abstract][Full Text] [Related]
15. Pharmaceutical postmarket review: fact or fiction?
Schanz SJ
Food Drug Law J; 2007; 62(3):493-500. PubMed ID: 17915391
[No Abstract] [Full Text] [Related]
16. The drug safety review process.
Somberg J
Am J Ther; 2007; 14(2):119. PubMed ID: 17414577
[No Abstract] [Full Text] [Related]
17. National adverse drug reaction reporting. 1984-1989.
Faich GA
Arch Intern Med; 1991 Aug; 151(8):1645-7. PubMed ID: 1872669
[TBL] [Abstract][Full Text] [Related]
18. U.S. postmarketing pharmacovigilance compliance in the midst of regulatory uncertainty.
Goldman SA
Food Drug Law J; 2007; 62(3):513-28. PubMed ID: 17915393
[No Abstract] [Full Text] [Related]
19. Safety surveillance in drug development: understanding the process and its implications for nephrology nursing.
Browar S
Nephrol Nurs J; 2002 Apr; 29(2):143-50. PubMed ID: 11997949
[TBL] [Abstract][Full Text] [Related]
20. An underrecognized challenge in evaluating postmarketing drug safety.
Roden DM
Circulation; 2005 Jan; 111(3):246-8. PubMed ID: 15668350
[No Abstract] [Full Text] [Related]
[Next] [New Search]
